Bioxytran Inc.

Industry · 2 registered clinical trials.

Status	Trial	Phase	Started
Unknown	To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M COVID-19, SARS CoV 2 Infection	Phase 2	2023-09-01
Unknown	PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection	Phase 3	2022-04-01